BioMarin stock jumps after Ascendis patent settlement deal
BioMarin Pharmaceutical Inc. (BMRN) shares rose 5% after settling a patent dispute with Ascendis Pharma. Ascendis will pay BioMarin royalties on Yuviwel sales until 2030, including 20% in the U.S. and 18% in other regions. The deal resolves all pending litigation and grants Ascendis a license for BioMarin’s related patents.
How this was made
The 30-second read
Why it matters
The deal removes legal uncertainty and adds a royalty revenue stream, likely supporting the stock's recent rally.
Market read
First‑report settlement news with material impact on BioMarin's valuation and risk profile.
What to watch
Potential future litigation in other jurisdictions could arise despite current settlement.
Background
BioMarin announced a global settlement with Ascendis Pharma resolving multiple patent disputes and ending an ITC investigation.
Ticker impact
BioMarin settled a patent dispute with Ascendis, receiving royalties on Yuviwel sales and dismissing an ITC investigation.
Expect modest upside as royalty income materializes and risk is reduced.
Royalty terms cover US and key international markets and the deal ends pending litigation, improving outlook.
Market effects
Sets a precedent for royalty-based settlements in biotech patent disputes.
May boost sentiment for US biotech stocks facing similar IP challenges.
Highlights cross‑border IP licensing trends affecting European and Asian markets.
Counterpoint
Royalty payments may be lower than expected if Yuviwel sales underperform.
Key entities
- companyBioMarin Pharmaceutical Inc.
US‑listed biotech company (BMRN) receiving royalties from the settlement.
- companyAscendis Pharma A/S
Danish biotech paying royalties to BioMarin under the settlement.
